Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bio-Manguinhos Measles-Rubella vaccine
- Development stage
- Unknown
- Lead developer
- Immunobiological Technology Institute (Bio-Manguinhos), Oswaldo Cruz Foundation (Fiocruz)
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The Bio-Manguinhos Measles-Rubella (MR) vaccine is a bivalent, live attenuated viral vaccine developed by the Immunobiological Technology Institute (Bio-Manguinhos) of the Oswaldo Cruz Foundation (Fiocruz) in Brazil. It is composed of the attenuated measles virus (Schwarz strain) and the attenuated rubella virus (Wistar RA27/3 strain). The vaccine is designed to provide active immunity against both measles and rubella infections. It has been evaluated in Phase II/III clinical trials (notably NCT03148990) in 11-month-old infants, demonstrating safety and immunogenicity comparable to standard MMR vaccines. In September 2022, Bio-Manguinhos submitted the vaccine for WHO prequalification to facilitate its inclusion in global immunization programs, and it is currently part of the institute's vaccine portfolio.
- Other names
- Measles and Rubella vaccineDouble viral vaccine (MR)MR vaccineBio-Manguinhos MR vaccine
Beyond the preview
Go deeper on Bio-Manguinhos Measles-Rubella vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bio-Manguinhos Measles-Rubella vaccine.